MENU
+Compare
TBPH
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$9.73
Change
-$0.23 (-2.31%)
Capitalization
478.47M

TBPH Theravance Biopharma Forecast, Technical & Fundamental Analysis

a developer of small molecule pharmaceutical products

Industry Biotechnology
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for TBPH with price predictions
Dec 17, 2024

Momentum Indicator for TBPH turns positive, indicating new upward trend

TBPH saw its Momentum Indicator move above the 0 level on December 06, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for TBPH moved above the 200-day moving average on December 09, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TBPH advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 148 cases where TBPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TBPH moved out of overbought territory on November 21, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where TBPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TBPH turned negative on December 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TBPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TBPH broke above its upper Bollinger Band on November 13, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.577) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). TBPH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (7.524) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TBPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TBPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

TBPH is expected to report earnings to fall 23.19% to -19 cents per share on March 03

Theravance Biopharma TBPH Stock Earnings Reports
Q4'24
Est.
$-0.20
Q3'24
Missed
by $0.03
Q2'24
Missed
by $0.13
Q1'24
Beat
by $0.01
Q4'23
Missed
by $0.02
The last earnings report on November 12 showed earnings per share of -25 cents, missing the estimate of -23 cents. With 212.37K shares outstanding, the current market capitalization sits at 478.47M.
A.I. Advisor
published General Information

General Information

a developer of small molecule pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
Ugland House, South Church Street
Phone
+1 650 808-6000
Employees
99
Web
https://www.theravance.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGYX19.70-0.07
-0.35%
NYLI PineStone Global Equity Class C
AWWIX13.21-0.05
-0.38%
CIBC Atlas International Growth Instl
BRIIX17.19-0.07
-0.40%
Baron Real Estate Income Institutional
CSJIX67.83-0.30
-0.44%
Cohen & Steers Realty Shares I
NWFAX36.09-0.23
-0.63%
Nationwide A

TBPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with AXON. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+1.63%
AXON - TBPH
34%
Loosely correlated
-2.09%
ARRY - TBPH
34%
Loosely correlated
+6.01%
MDGL - TBPH
30%
Poorly correlated
-1.58%
CDXS - TBPH
30%
Poorly correlated
+0.36%
ELEV - TBPH
29%
Poorly correlated
+4.66%
More